Published online before print November 1, 2001, doi: 10.1161/hh2301.100980
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2001 American Heart Association, Inc.
Clinical Research |
Coronary Vasodilation and Improvement in Endothelial Dysfunction With Endothelin ETA Receptor Blockade
From the Cardiology Branch, National Heart, Lung, and Blood Institute, NIH, Bethesda, Md.
Correspondence to Arshed A. Quyyumi, MD, Professor of Medicine (Cardiology), Emory University Hospital, Suite F606, 1364 Clifton Rd NE, Atlanta, GA 30322. E-mail aquyyum{at}emory.edu
The endothelium-derived peptide endothelin-1 (ET-1) causes vasoconstriction predominantly via smooth muscle ETA receptor activation. We hypothesized that ETA receptor inhibition would improve human coronary vascular function. We studied unobstructed coronary arteries of 44 patients with atherosclerosis or its risk factors. Epicardial diameter (D) and Doppler flow velocity were measured, and coronary vascular resistance (CVR) was calculated during intracoronary infusions of acetylcholine (ACH) and sodium nitroprusside (SNP), and during cold pressor testing, before and after a 60-minute intracoronary infusion of the ETA receptor antagonist BQ-123. BQ-123 dilated the coronary circulation; D increased by 5.6±1.0% (P<0.0001), and CVR fell by 12±3% (P<0.01). The D response to ACH, corrected for the SNP response, improved in segments that constricted with ACH at baseline (P=0.03), whereas segments that initially dilated with ACH did not change with BQ-123 (P=NS). Improvement in D and CVR responses to ACH with BQ-123 inversely correlated with baseline ACH responses (r=-0.44 [P=0.006] and r=-0.78 [P=0.001], respectively), indicating greater improvement in those with endothelial dysfunction. Similarly, cold pressor testing–mediated epicardial vasoconstriction (-2.0±1.1%) was reversed after BQ-123 (+1.0±0.7%), especially in dysfunctional segments (from -5.6±0.9% to +2.2±0.9%, P<0.001). There was no correlation between any risk factor and the response to BQ-123. An arteriovenous difference in ET-1 levels developed after BQ-123, which was consistent with enhanced cardiac clearance of ET-1, probably via ETB receptors. Thus, ET-1 acting via the ETA receptor contributes to basal human coronary vasoconstrictor tone and endothelial dysfunction. This suggests that ETA receptor antagonism may have therapeutic potential in the treatment of endothelial dysfunction and atherosclerosis.
Key Words: endothelin • coronary circulation • endothelial function • atherosclerosis
This article has been cited by other articles:
 |
|
 |
|
  T. W. Cherng, M. J. Campen, T. L. Knuckles, L. Gonzalez Bosc, and N. L. Kanagy Impairment of coronary endothelial cell ETB receptor function after short-term inhalation exposure to whole diesel emissions Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2009; 297(3): R640 - R647. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Dhaun, I. M. MacIntyre, V. Melville, P. Lilitkarntakul, N. R. Johnston, J. Goddard, and D. J. Webb Blood Pressure-Independent Reduction in Proteinuria and Arterial Stiffness After Acute Endothelin-A Receptor Antagonism in Chronic Kidney Disease Hypertension, July 1, 2009; 54(1): 113 - 119. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Dhaun, J. Goddard, D. E. Kohan, D. M. Pollock, E. L. Schiffrin, and D. J. Webb Role of Endothelin-1 in Clinical Hypertension: 20 Years On Hypertension, September 1, 2008; 52(3): 452 - 459. [Full Text] [PDF]
|
|
|
|
 |
|
 G.-W. He, M.-H. Liu, Q. Yang, A. Furnary, and A. P.C. Yim Role of Endothelin-1 Receptor Antagonists in Vasoconstriction Mediated by Endothelin and Other Vasoconstrictors in Human Internal Mammary Artery Ann. Thorac. Surg., November 1, 2007; 84(5): 1522 - 1527. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Bohm and J. Pernow The importance of endothelin-1 for vascular dysfunction in cardiovascular disease Cardiovasc Res, October 1, 2007; 76(1): 8 - 18. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P.J. Halcox, K. R.A. Nour, G. Zalos, and A. A. Quyyumi Endogenous Endothelin in Human Coronary Vascular Function: Differential Contribution of Endothelin Receptor Types A and B Hypertension, May 1, 2007; 49(5): 1134 - 1141. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N F Kelland and D J Webb Clinical trials of endothelin antagonists in heart failure: publication is good for the public health Heart, January 1, 2007; 93(1): 2 - 4. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Battistini, N. Berthiaume, N. F. Kelland, D. J. Webb, and D. E. Kohan Profile of Past and Current Clinical Trials Involving Endothelin Receptor Antagonists: The Novel "-Sentan" Class of Drug. Experimental Biology and Medicine, June 1, 2006; 231(6): 653 - 695. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Dhaun, J. Goddard, and DavidJ. Webb The Endothelin System and Its Antagonism in Chronic Kidney Disease J. Am. Soc. Nephrol., April 1, 2006; 17(4): 943 - 955. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Nohria, L. Garrett, W. Johnson, S. Kinlay, P. Ganz, and M. A. Creager Endothelin-1 and Vascular Tone in Subjects With Atherogenic Risk Factors Hypertension, July 1, 2003; 42(1): 43 - 48. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. P. Rossi, C. Ganzaroli, M. Cesari, A. Maresca, M. Plebani, G. G. Nussdorfer, and A. C. Pessina Endothelin receptor blockade lowers plasma aldosterone levels via different mechanisms in primary aldosteronism and high-to-normal renin hypertension Cardiovasc Res, January 1, 2003; 57(1): 277 - 283. [Abstract] [Full Text] [PDF]
|
|